997 Lenox Drive, Suite 100
Lawrenceville, NJ 08648
Phone: (609) 896-9100
Celsion Corporation (“Celsion” or “the Company”) is a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. Through the application of its two distinct nanoparticle-based technology platforms, Celsion has developed a robust pipeline that includes two clinical programs: (1) GEN-1, a DNA-based immunotherapy in a Phase I/II study for the treatment of Stage III/IV ovarian cancer. GEN-1 is a non-viral, synthetic delivery platform that facilitates the localized secretion of interleukin-12 (IL-12)—an immune protein that plays a key role in generating an immune response against cancer—into the tumor region; and (2) ThermoDox®, a heat-activated nanoparticle encapsulation of doxorubicin (a widely used chemotherapeutic agent) in a Phase III clinical trial for the treatment of hepatocellular cancer (HCC)/primary liver cancer. When heated through the application of heat-based treatments, ThermoDox® changes structure, creating openings that release doxorubicin directly into the tumor. Through investigator sponsored studies, Celsion is further supporting clinical studies to expand the application of its ThermoDox® technology platforms into other cancer indications in breast, pancreatic, and bladder cancer.
* The Corporate Snapshot was last updated on December 9, 2020.